Respiratory syncytial virus (RSV) polypeptide having immunogenicity
By designing recombinant RSV polypeptides and using cysteine to replace mutations to form disulfide bonds and multimerization domains, the challenges of existing RSV vaccines in terms of safety and effectiveness are solved, and effective protection of RSV is achieved.
Patent Information
- Application Number
- PCT/CN2024/095548
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-19
- Filing Date
- 2024-05-27
- Publication Date
- 2024-11-28
AI Technical Summary
Existing RSV vaccines have challenges in terms of safety and effectiveness, especially when the pre-fusion conformation F protein is used as an antigen, it is difficult to effectively induce neutralizing antibody responses and lacks stability.
A recombinant RSV polypeptide is designed to contain the RSV F protein recombinant ectodomain. It forms disulfide bonds by introducing cysteine substitution mutations, stabilizes the protein configuration and oligomerization state, and combines the multimerization domain to ensure high expression. And the specific epitope is retained to form an immunogenic prefusion conformation.
Effective neutralizing antibody response and binding antibody response to RSV are achieved, which improves the safety and stability of the vaccine, enhances immunogenicity, and can effectively protect the infection of RSV.
Smart Images

Figure CN2024095548_28112024_PF_FP_ABST
Abstract
Description
An immunogenic respiratory syncytial virus (RSV) polypeptide Technical Field
[0001] The present application belongs to the field of biomedicine technology, and in particular relates to an immunogenic respiratory syncytial virus (RSV) polypeptide, a preparation method thereof, and an application thereof in preparing a vaccine for preventing RSV infection. Background Art
[0002] Respiratory viral infections are one of the most significant global public health burdens, resulting in millions of hospitalizations worldwide each year. Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in children under 2 years of age and adults over 65 years of age. Despite the serious harm caused by RSV-induced respiratory illness, there are currently no effective treatments or preventive vaccines specifically targeting RSV. RSV vaccines currently in clinical development worldwide focus on live attenuated vaccines, recombinant subunit vaccines, and viral vector vaccines. RSV vaccine development primarily targets three target populations: infants, pregnant women, and the elderly (≥60 years of age). For infants younger than 6 months of age, passive protection is primarily achieved through mAbs or through transplacental antibody transfer after RSV vaccination in pregnant women. For infants older than 6 months of age, active protection can be achieved through live attenuated RSV vaccines. For pregnant women and the elderly, RSV vaccine development primarily focuses on subunit vaccines.
[0003] The selection of mainstream vaccine antigens mainly focuses on the F protein, especially the F protein in the prefusion conformation (PreF). Compared with the F protein in the postfusion conformation, the F protein in the prefusion conformation can expose more potential epitopes with neutralizing activity, such as epitope Φ and epitope V, which are only present in PreF. Antibodies generated against epitope Φ and epitope V have excellent neutralizing activity. After binding to the F protein in the prefusion conformation, they can block viral membrane fusion mediated by conformational changes of the F protein. Although there have been a lot of studies on the stability of the RSV F protein in the prefusion conformation, its safety and efficacy as a vaccine still face huge challenges.
[0004] Therefore, providing an RSV antigen with high safety, enhanced immunogenicity and improved stability, as well as a vaccine containing the same, has become a technical problem that urgently needs to be solved by those skilled in the art.
[0005] Summary of the Invention
[0006] In order to solve the above technical problems, the present invention provides an immunogenic respiratory syncytial virus (RSV) polypeptide.
[0007] In one aspect, the present invention discloses a recombinant respiratory syncytial virus (RSV) polypeptide comprising a recombinant extracellular domain of an RSV F protein, corresponding to amino acid residues 26-513 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1, wherein the recombinant extracellular domain comprises at least three types of cysteine substitution mutations, wherein the cysteine substitution mutations form disulfide bonds between the introduced cysteine residues, which are used to stabilize the conformation or oligomeric state of the protein, such as the prefusion conformation, one type of which is an intermolecular cysteine substitution mutation selected from one or two pairs of V144C+I407C, K75C+E218C, S146C+N460C, and A149C+Y458C. Another type is an N-type cysteine substitution mutation, wherein the N-type cysteine substitution site is between residues 1-300 of the wild-type RSV F protein amino acid sequence, preferably positions 137 to 216, including one or two pairs of cysteine substitutions; the third type is a C-type cysteine substitution mutation, wherein the C-type cysteine substitution site is between residues 320-500 of the wild-type RSV F protein amino acid sequence, preferably positions 460 to 500, including one or two pairs of cysteine substitutions.
[0008] The N-type cysteine substitution mutation described in the technical solution of the present invention refers to a pair in which one of the mutation sites is at positions 137 to 216 of the F protein, and the C-type cysteine substitution mutation refers to a pair in which one of the mutation sites is at positions 460 to 500 of the F protein.
[0009] The one mutation site in the technical solution of the present invention at positions 137 to 216 of the F protein refers to I148C+Y286C, S55C+L188C, H159C+I291C or G151C+I288C.
[0010] The mutation site described in the technical solution of the present invention at positions 460 to 500 of the F protein refers to K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C or F387C+I492C.
[0011] The present invention discloses an immunogenic respiratory syncytial virus (RSV) polypeptide comprising a recombinant extracellular domain of the RSV F protein corresponding to amino acid residues 26-513 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1, wherein the recombinant extracellular domain comprises the following combination of cysteine substitution mutations:
[0012] A, intermolecular cysteine substitution mutations are selected from one or two pairs of V144C+I407C, K75C+E218C, S146C+N460C, and A149C+Y458C;
[0013] B, N-type cysteine substitution mutations, one of which is located at positions 137 to 216 of the F protein;
[0014] C, C type cysteine substitution mutations, one of which is located at positions 460 to 500 of the F protein.
[0015] In the technical solution of the present invention, the one mutation site at positions 137 to 216 of the F protein is selected from one or two pairs of I148C+Y286C, S55C+L188C, H159C+I291C and G151C+I288C; wherein the one mutation site at positions 460 to 500 of the F protein refers to K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C or F387C+I492C.
[0016] The present invention discloses a recombinant respiratory syncytial virus (RSV) polypeptide, comprising a recombinant extracellular domain of an RSV F protein, corresponding to amino acid residues 26-513 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1, and having cysteine mutations K75C+E218C and / or V144C+I407C compared to the wild-type RSV F protein.
[0017] The present invention discloses a recombinant respiratory syncytial virus (RSV) polypeptide, which has cysteine mutations I148C+Y286C or S55C+L188C compared with the wild-type RSV F protein.
[0018] The present invention discloses a recombinant respiratory syncytial virus (RSV) polypeptide, which has cysteine mutations K399C+S485C or F387C+I492C compared with the wild-type RSV F protein.
[0019] The polypeptide disclosed in the present invention, wherein the recombinant extracellular domain comprises one of the following combinations of cysteine substitution mutations:
[0020] A. V144C+I407C, K75C+E218C, I148C+Y286C, and F387C+I492C;
[0021] B. V144C+I407C, I148C+Y286C, S55C+L188C, and F387C+I492C;
[0022] C.K75C+E218C, I148C+Y286C, T323C+I475C,
[0023] D.K75C+E218C, I148C+Y286C, F387C+I492C,
[0024] E.K75C+E218C, I148C+Y286C, K399C+S485C,
[0025] F.K75C+E218C, G151C+I288C, K399C+S485C,
[0026] G.K75C+E218C, H159C+I291C, K399C+S485C,
[0027] The polypeptide described in the technical solution of the present invention, wherein the recombinant extracellular domain further comprises a cavity-filling mutation, and the cavity-filling mutation site is selected from one, two, three or four of positions 67, 495, 296 and 190 of the wild-type RSV F protein amino acid sequence.
[0028] In some embodiments, the preferred cavity-filling mutation is N67F, and in other embodiments, the preferred cavity-filling mutation is N67F+S190V+V296F+V495L.
[0029] The polypeptide described in the technical solution of the present invention, wherein the recombinant extracellular domain further comprises mutations P102A+I379V+M447V, S46G or G184N that increase the expression amount.
[0030] The recombinant ectodomain of the present invention comprises an epitope that is only present in the prefusion conformation, and the epitope comprises residues 62-69 and 196-209 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1.
[0031] The polypeptide described in the technical solution of the present invention, wherein the recombinant extracellular domain includes a recombinant F2 domain comprising at least amino acid residues 26-105 of the RSV F protein and a recombinant F1 domain comprising at least amino acid residues 145-513 of the RSV F protein.
[0032] In the polypeptide described in the technical solution of the present invention, the recombinant F2 domain is connected to the recombinant F1 domain directly or through a linker.
[0033] In some embodiments, the recombinant F2 domain and the recombinant F1 domain are connected by a linker, which means that the C-terminus of the F2 domain and the N-terminus of the F1 domain are connected by a linker, for example, residues 106-144 of the recombinant extracellular domain of the F protein are replaced by a linker sequence selected from GGPGGS, GAPEPGE or GGSGGSG.
[0034] In some embodiments, the C-terminus of the polypeptide comprises a multimerization domain.
[0035] In some embodiments, the multimerization domain is located at the C-terminus of the recombinant extracellular domain and is directly connected to the C-terminus of the recombinant extracellular domain or connected through a linker sequence.
[0036] In some embodiments, optionally, the linker sequence is GGGSSGS, GSGSG, or a 4-10 amino acid sequence consisting of G and S.
[0037] In some embodiments, wherein the multimerization domain is a trimerization domain, the trimerization domain promotes the formation of a trimer of three F1 / F2 heterodimers.
[0038] In some embodiments, the multimerization domain is a domain that can achieve higher polymerization, such as ferritin that can self-assemble to form twenty-tetramers.
[0039] In some embodiments, the multimerization domain is preferably a foldon domain or a ferritin domain.
[0040] In the present application, "ferritin" refers to the ferritin of Trichoplusia ni or Helicobacter pylori. In the present application, the ferritin of Helicobacter pylori has a single-chain structure. In the present application, the ferritin may be a mutant of the ferritin of Trichoplusia ni or Helicobacter pylori. In the present application, "mutant" generally refers to a sequence that differs from a reference sequence by containing one or more differences (mutations). The difference may be a substitution, deletion or insertion of one or more amino acids. Exemplary, the amino acid sequence of ferritin used in the present application is
[0041] In some embodiments, the recombinant extracellular domain comprises the F2 domain or a functionally active fragment thereof and the F1 domain or a functionally active fragment thereof of the RSV F protein.
[0042] In some embodiments, the F2 domain comprises a RSV F protein polypeptide corresponding to amino acids 26-105 of SEQ ID NO: 1, and the F1 domain comprises a RSV F protein polypeptide corresponding to amino acids 137-516 of SEQ ID NO: 1.
[0043] In some embodiments, the recombinant extracellular domain includes a recombinant F2 domain comprising at least amino acid residues 26-105 of the RSV F protein and a recombinant F1 domain comprising at least amino acid residues 145-513 of the RSV F protein.
[0044] In some embodiments, the recombinant extracellular domain includes a recombinant F2 domain comprising amino acid residues 26-105 of the RSV F protein and a recombinant F1 domain comprising amino acid residues 145-513 of the RSV F protein.
[0045] In some embodiments, the recombinant F2 domain and the recombinant F1 domain are connected via a linker sequence.
[0046] In some embodiments, the recombinant F2 domain and the recombinant F1 domain are connected via a linker sequence of 4-10 amino acid residues consisting of GGGSSGS, GSGSG, GGPG, or G and S.
[0047] In some embodiments, the linker sequence of 4-10 amino acid residues composed of G and S can be GGSGGSG.
[0048] In some embodiments, the recombinant extracellular domain includes a recombinant F2 domain comprising at least amino acid residues 26-103 of the RSV F protein and a recombinant F1 domain comprising at least amino acid residues 146-513 of the RSV F protein.
[0049] In some embodiments, the recombinant extracellular domain includes a recombinant F2 domain comprising amino acid residues 26-103 of the RSV F protein and a recombinant F1 domain comprising amino acid residues 145-513 of the RSV F protein.
[0050] In some embodiments, the recombinant extracellular domain includes a recombinant F2 domain comprising amino acid residues 26-103 of the RSV F protein and a recombinant F1 domain comprising amino acid residues 147-513 of the RSV F protein.
[0051] In some embodiments, the recombinant F2 domain and the recombinant F1 domain are connected by a linker sequence of 5-8 amino acid residues consisting of glycine G, proline P, and one or more amino acids selected from serine S, alanine A, glutamic acid E, and lysine K.
[0052] In some embodiments, the linker sequence is a linker sequence of 5-8 amino acid residues consisting of glycine G, proline P and serine S.
[0053] In some embodiments, the linker sequence is a linker sequence with a length of 6 amino acid residues consisting of glycine G, proline P and serine S, wherein the linker sequence is GGPGGS.
[0054] In some embodiments, the linker sequence is a linker sequence of 5-8 amino acid residues consisting of glycine G, proline P, serine S and alanine A.
[0055] In some embodiments, the linker sequence is a linker sequence of 5 amino acid residues in length consisting of glycine G, proline P, serine S and alanine A, wherein the linker sequence is GAPGS.
[0056] In some embodiments, the linker sequence is a linker sequence of 5-8 amino acid residues consisting of glycine G, proline P, alanine A, and glutamic acid E.
[0057] In some embodiments, the linker sequence is a linker sequence of 7 amino acid residues in length consisting of glycine G, proline P, alanine A and glutamic acid E, wherein the linker sequence is GAPEPGE.
[0058] In some embodiments, the linker sequence is a linker sequence of 5-8 amino acid residues consisting of glycine G, proline P, alanine A, glutamic acid E and lysine K.
[0059] In some embodiments, the linker sequence is a linker sequence of 7 amino acid residues in length consisting of glycine G, proline P, alanine A, glutamic acid E and lysine K, wherein the linker sequence is GKPAPGE.
[0060] In some embodiments, the cavity-filling mutation is selected from one or more of N67F, S190V, V296F, and V495L. In some embodiments, the cavity-filling mutation is N67F. In some embodiments, the cavity-filling mutation is preferably a combination of N67F, S190V, V296F, and V495L.
[0061] In some embodiments, the expression-enhancing substitution is selected from P102A+I379V+M447V, S46G, L95M, I221M, and / or E218A. In some embodiments, the electrostatic mutation is selected from G184N. In other embodiments, G184N also has an expression-enhancing effect.
[0062] In some embodiments, the present invention designs intermolecular disulfide bonds, which refer to disulfide bonds connecting monomers, to help lock the F protein in the pre-fusion conformation, such as K75C+E218C, K75C+E218C, V144C+I407C, or S150C+Y458C. In some embodiments, the present invention designs disulfide bond mutations in the distal region of the fixed membrane, such as N-type disulfide bonds, which refer to disulfide bond mutations in which one of the mutation sites is at positions 137 to 216 of the F protein, such as I148C+Y286C, S55C+L188C, H159C+I291C, or G151C+I288C. In some embodiments, the present invention designs a disulfide bond mutation C in the proximal region of the fixed membrane, which means that one of the mutation sites of the disulfide bond mutation is at positions 460 to 500 of the F protein, such as K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C or F387C+I492C.
[0063] In some embodiments, the mutation that increases expression comprises S46G.
[0064] In some embodiments, the mutations that increase expression include G184N, S46G, L95M, and I221M.
[0065] The polypeptide disclosed in the present invention comprises a signal peptide sequence required for expression or a linker sequence connected to a purification tag. These signal peptide sequences or linker sequences connected to a purification tag can be removed in the final product.
[0066] In some embodiments, the polypeptide is constructed to further comprise a heterologous signal peptide.
[0067] In some embodiments, the heterologous signal peptide is an IgG signal peptide with an amino acid sequence of MGWSCIILFLVATATGVHS.
[0068] In some embodiments, affinity tags for facilitating subsequent purification are also introduced into the polypeptide vector during construction, such as strep tag (amino acid sequence: WSHPQFEK), Monoclonal Flag-Tag (amino acid sequence: DYKDDDDK), and His tag (amino acid sequence: HHHHHHHH). These tag sequences can be removed from the final product.
[0069] The present invention also provides the use of the polypeptide in preparing a vaccine for preventing RSV infection.
[0070] The present invention also provides a vaccine for preventing RSV infection, comprising any one of the above polypeptides; the vaccine provides protection against infection by at least one of RSV subtype A and / or subtype B.
[0071] The present invention discloses a vaccine composition for preventing RSV infection, further comprising an immune adjuvant, wherein the immune adjuvant comprises at least one of aluminum adjuvant, squalene, tocopherol, MPL, LPA, CpG, poly(I:C) and QS-21.
[0072] In some embodiments, the present invention discloses a vaccine for preventing RSV infection, comprising a liposome-form adjuvant, wherein the main components of the liposome-form adjuvant include MPL, QS-21, DOPC, and cholesterol. The adjuvant dosage can be 0.5 ml per dose, containing 50 μg MPL, 50 μg QS-21, 1 mg DOPC, 0.25 mg cholesterol, 4.835 mg sodium chloride, 0.15 mg anhydrous disodium hydrogen phosphate, 0.54 mg potassium dihydrogen phosphate, and water for injection. It can also be one-half, one-quarter, or less of the above dosage, for example, the main components include 25 μg MPL, 25 μg QS-21, 0.5 mg DOPC, and 0.125 mg cholesterol.
[0073] RSV virus has two subtypes, A and B, and each subtype has different genotypes. Type A is more common in the population, while type B is more likely to cause lower respiratory tract infections in infants and young children. There is a small amount of antigenic difference between the two subtypes. The technical solution of the present invention also includes providing a respiratory cytial virus antigen composition, characterized in that the respiratory cytial virus antigen composition comprises a first component and a second component, the first component is derived from the F protein of the first strain of respiratory cytial virus, and the second component protein is derived from the F protein of the second strain of respiratory cytial virus, and may also include a third strain or a fourth strain.
[0074] In a specific embodiment, the RSV antigen composition of the present invention includes recombinant respiratory syncytial virus (RSV) polypeptides of subtype A and / or subtype B.
[0075] The present invention discloses a recombinant respiratory syncytial virus (RSV) polypeptide, comprising a recombinant extracellular domain of RSV F protein of subtype A or / and subtype B, corresponding to amino acid residues 26-513 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1, and having cysteine mutations K75C+E218C or V144C+I407C compared to the wild-type RSV F protein.
[0076] The present invention discloses a recombinant subtype A or / and subtype B respiratory syncytial virus (RSV) polypeptide, which has cysteine mutations I148C+Y286C or S55C+L188C compared with the wild-type RSV F protein.
[0077] The present invention discloses a recombinant subtype A or / and subtype B respiratory syncytial virus (RSV) polypeptide, which has cysteine mutations K399C+S485C or F387C+I492C compared with the wild-type RSV F protein.
[0078] The polypeptide disclosed in the present invention, wherein the extracellular domain of the recombinant A subtype or / and B subtype comprises one of the following combinations of cysteine substitution mutations:
[0079] A. V144C+I407C, K75C+E218C, I148C+Y286C, and F387C+I492C;
[0080] B. V144C+I407C, I148C+Y286C, S55C+L188C, and F387C+I492C;
[0081] C.K75C+E218C, I148C+Y286C, T323C+I475C;
[0082] D.K75C+E218C, I148C+Y286C, F387C+I492C;
[0083] E.K75C+E218C, I148C+Y286C, K399C+S485C;
[0084] F.K75C+E218C, G151C+I288C, K399C+S485C;
[0085] G.K75C+E218C, H159C+I291C, K399C+S485C.
[0086] The polypeptide described in the technical solution of the present invention, wherein the recombinant RSV extracellular domain of subtype A or / and subtype B further comprises a cavity-filling mutation, and the cavity mutation site is selected from one, two, three or four of positions 67, 495, 296 and 190 of the wild-type RSV F protein amino acid sequence.
[0087] In some embodiments, the preferred cavity-filling mutation is N67F, and in other embodiments, the preferred cavity-filling mutation is N67F+S190V+V296F+V495L.
[0088] The polypeptide described in the technical solution of the present invention, wherein the recombinant extracellular domain of subtype A or / and subtype B further comprises the mutation P102A+I379V+M447V, S46G or G184N that increases the expression amount.
[0089] The extracellular domain of the recombinant subtype A or / and subtype B described in the present invention comprises an epitope that is only present in the prefusion conformation, and the epitope comprises residues 62-69 and 196-209 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1.
[0090] The polypeptide described in the technical solution of the present invention, wherein the recombinant extracellular domain of subtype A or / and subtype B includes a recombinant F2 domain comprising at least amino acid residues 26-105 of the RSV F protein and a recombinant F1 domain comprising at least amino acid residues 145-513 of the RSV F protein.
[0091] In the polypeptide described in the technical solution of the present invention, the recombinant F2 domain is connected to the recombinant F1 domain directly or through a linker.
[0092] In some embodiments, the recombinant F2 domain and the recombinant F1 domain are connected by a linker, which means that the C-terminus of the F2 domain and the N-terminus of the F1 domain are connected by a linker, for example, residues 106-144 of the recombinant extracellular domain of the F protein of subtype A or / and subtype B are replaced by a linker sequence selected from GGPGGS, GAPEPGE or GGSGGSG.
[0093] In some embodiments, the C-terminus of the recombinant polypeptide of subtype A or / and subtype B includes a multimerization domain.
[0094] In some embodiments, the multimerization domain is located at the C-terminus of the recombinant extracellular domain and is directly connected to the C-terminus of the recombinant A subtype or / and B subtype F protein extracellular domain or connected through a linker sequence.
[0095] In some embodiments, optionally, the linker sequence is GGGSSGS, GSGSG, or a 4-10 amino acid sequence consisting of G and S.
[0096] In some embodiments, wherein the multimerization domain is a trimerization domain, the trimerization domain promotes the formation of a trimer of three F1 / F2 heterodimers.
[0097] In some embodiments, the multimerization domain is a domain that can achieve higher polymerization, such as ferritin that can self-assemble to form twenty-tetramers.
[0098] In some embodiments, the multimerization domain is preferably a foldon domain or a ferritin domain.
[0099] In this application, the immunogenic composition antigen dose is 60-120 μg. In a specific embodiment, the antigen is type A prefusion F protein, or type B prefusion F protein. In a specific embodiment, the antigen is the subtype A antigen designed by the present invention, or it can be a subtype B antigen, or a subtype of RSV F protein that has been disclosed or unknown. The antigen dose is 7.5 μg, 30 μg, 50 μg, 60 μg, 70 μg, 80 μg, 90 μg, 100 μg, 110 μg, 120 μg, 150 μg, and the preferred antigen dose is 60-120 μg.
[0100] The technical solution of the present invention also includes providing a respiratory syncytial virus antigen composition, wherein the weight ratio of the first component to the second component is (1-4): (1-4), preferably 1:1. Each component contains 7.5-80 μg of F protein, preferably 30-60 μg. In a suitable embodiment, the antigen comprises a mixture of type A antigen and type B antigen, with 7.5 μg, 30 μg, 50 μg, 60 μg, 70 μg or 80 μg of each subtype antigen.
[0101] The technical solution of the present invention also includes providing a respiratory syncytial virus immune composition, characterized in that it comprises an adjuvant and an antigen derived from at least one respiratory syncytial virus strain, wherein the antigen comprises a recombinant respiratory syncytial virus (RSV) polypeptide of subtype A and / or subtype B, and the adjuvant is selected from an oil-in-water emulsion adjuvant or a liposome adjuvant.
[0102] The technical solution of the present invention also includes providing that the oil phase of the oil-in-water emulsion is squalene and α-tocopherol, and the emulsifier is Tween 80.
[0103] In a specific embodiment, the oil-in-water emulsion comprises 0.1-25 wt.% of squalene, 0.1-25 wt.% of α-tocopherol and 0.05-6 wt.% of Tween 80.
[0104] In a specific embodiment, each dose of the vaccine comprises 0.5-18 mg of squalene, 0.5-18 mg of tocopherol, and 0.2-6 mg of Tween; preferably, each dose of the vaccine comprises 5-15 mg of squalene, 5-15 mg of tocopherol, and 2-5.5 mg of Tween; in a specific embodiment, more preferably, each dose of the vaccine comprises 9-13 mg of squalene, 9-13 mg of tocopherol, and 4-5 mg of Tween, and in a specific embodiment comprises 10.69 mg of squalene, 11.86 mg of α-tocopherol, and 4.86 mg of Tween 80, and in a specific embodiment comprises 5.35 mg of squalene, 5.93 mg of α-tocopherol, 2.43 mg of Tween 80,
[0105] In a specific embodiment, the standard dose emulsion for one person comprises 10.69 mg of squalene, 11.86 mg of α-tocopherol, 4.86 mg of Tween 80, 3.53 mg of sodium chloride, 0.09 mg of potassium chloride, 0.51 mg of disodium hydrogen phosphate, and 0.09 mg of potassium dihydrogen phosphate. The emulsion dose contained in each dose of vaccine is 1 / 2 or 1 / 4 of the standard dose emulsion for one person.
[0106] The present invention also provides a method for preparing the polypeptide, comprising the following steps:
[0107] S1. Synthesize the DNA sequence corresponding to the polypeptide and clone it into a plasmid vector;
[0108] S2. transfecting a host cell with the recombinant plasmid vector and expressing the recombinant plasmid vector, wherein the host cell is a eukaryotic cell;
[0109] S3. Purify the culture product to obtain the polypeptide.
[0110] In some embodiments, the vaccine of the present invention generally also includes a pharmaceutically acceptable carrier and / or excipient such as a buffer. Pharmaceutically acceptable carriers and excipients are well known and can be selected by those skilled in the art. Optionally, a pharmaceutically acceptable carrier or excipient also contains at least one component that stabilizes solubility and / or stability. Examples of solubilizers / stabilizers include detergents, such as laurel sarcosine and / or Tween. Other examples of solubilizers / stabilizers include arginine, sucrose, trehalose, etc. Therefore, those skilled in the art can select suitable excipients and carriers to produce formulations suitable for use by a selected route of administration to a subject. Suitable excipients include, but are not limited to, glycerol, polyethylene glycol, KCl, calcium ions, magnesium ions, manganese ions, zinc ions, and other divalent cation-related salts.
[0111] Generally, an adjuvant should be selected that is capable of enhancing a Th1-biased immune response in a subject or a population of subjects to which the vaccine is administered, and that is safe and effective in the subject or population of subjects.
[0112] The present invention also provides a method for preparing the above-mentioned vaccine for preventing RSV infection, which comprises:
[0113] S1. culturing mammalian host cells to express the polypeptide;
[0114] S2. Purify the polypeptide expressed in step (1);
[0115] S3. Fully mix the purified polypeptide and immune adjuvant in proportion.
[0116] In some embodiments, additional steps such as gene synthesis, construction of an expression vector, and lyophilization of the purified protein are also included. The expressed fusion polypeptide can be recovered and purified from the recombinant cell culture by any one or more of a variety of methods known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, filtration, ultrafiltration, centrifugation, anion / cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography, and lectin chromatography. Finally, high performance liquid chromatography (HPLC) can be used in the final purification step.
[0117] Compared with the prior art, the present invention has the following beneficial effects:
[0118] The present invention obtains an RSV polypeptide with high expression level and immunogenicity that can retain specific epitopes for Pre-F by stabilizing and modifying the wild-type RSV F protein and designing multimerization (such as trimerization). While maintaining a stable prefusion conformation, it ensures that it can induce effective neutralizing antibody responses and binding antibody responses against respiratory syncytial virus. BRIEF DESCRIPTION OF THE DRAWINGS
[0119] The following drawings are only intended to illustrate and explain the present invention, and are not intended to limit the scope of the present invention.
[0120] in:
[0121] Figure 1 (A): Collected effluent peaks and chromatogram of DS-Cav1A;
[0122] Figure 1(B): Collected effluent peaks and chromatogram of DS-Cav1B;
[0123] Figure 2 (A): Electrophoresis results of DS-Cav1A;
[0124] Figure 2(B): Electrophoresis results of DS-Cav1B;
[0125] Figure 3: Neutralizing antibody titers against RSV A2 induced by RSV vaccine antigen F196 and different adjuvants in BALB / c mice;
[0126] Figure 4: Cross-protective neutralizing antibody titers of RSV vaccine against type B virus in the mouse (BALB / c) model;
[0127] Figure 5: Neutralizing antibody titers against RSV type A virus in large-eared white rabbits after immunization with RSV vaccine;
[0128] Figure 6: Cross-protective neutralizing antibody titers against RSV type B virus after immunization of large-eared white rabbits with 120 μg of RSV vaccine antigen;
[0129] Figure 7: Type B virus neutralizing antibody titers in mice (BALB / c) immunized with RSV bivalent vaccine;
[0130] Figure 8: Two amino acids separated in the pre-fusion conformation of F49 (K75C+E218C)
[0131] Figure 9: The N-cysteine substituted RSV F protein has substitution sites separated by less than
[0132] Figure 10: Class C cysteine substituted RSV F protein prefusion conformation with substitution sites less than DETAILED DESCRIPTION
[0133] The present invention will be further described below by non-limiting examples, and it is well known to those skilled in the art that many modifications can be made to the present invention without departing from the spirit of the present invention, and such modifications also fall within the scope of the present invention. The following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the present invention, as embodiments are necessarily diverse. The terms used in this specification are only for the purpose of illustrating specific embodiments, rather than as limitations, and the scope of the present invention is defined in the appended claims.
[0134] Unless otherwise specified, all technical and scientific terms used in this specification have the same meanings as those commonly understood by those skilled in the art to which this invention belongs. Preferred methods and materials of the present invention are described below. However, any methods and materials similar or equivalent to those described in this specification can be used to practice or test the present invention. The following experimental methods are conventional methods or methods described in product specifications unless otherwise specified. The experimental materials used are readily available from commercial companies unless otherwise specified.
[0135] Definition of terms
[0136] In this application, the term "DS-Cav1" refers to the PreF design concept of CN105473604B, which includes a pre-F trimer stabilized by a disulfide bond between residues 155 and 290 ("DS"), cavity-filling mutations S190F and V207L ("Cav1"), and an additional C-terminal fibritin (i.e., foldon) trimerization domain, the specific sequence of which is given in the Examples.
[0137] In the present application, the term "D25" refers to the antibody described in CN101778866B, and its specific amino acid sequence is referred to SEQ ID NO: 1-8 in the specification.
[0138] In the present application, the term "101F" refers to the antibody described in US20060159695A1, and the nucleotide and amino acid sequences of the heavy and light chains thereof refer to SEQ ID NOs: 3-6 in the specification.
[0139] In the present application, the term "AM14" refers to the antibody described in CN101778866B, and the specific sequence refers to the amino acid sequence of AM14 in Example 4 of the patent specification.
[0140] In the present application, the term "Mota" or "Motavizumab" refers to the antibody described in WO2007002543A2, and its specific sequence refers to the amino acid sequence SEQ ID NO: 48 and SEQ ID NO: 11 of the A4B4L1FR-S28R antibody in the patent specification.
[0141] In the present application, each mutant of the present invention is designed and prepared based on the wild-type (abbreviated as WT) RSV F protein amino acid sequence described in SEQ ID NO: 1. The F protein polypeptide of the RSV can be selected from any F protein of RSV A strain, RSV B strain, HRSV A strain, HRSV B strain, BRSV strain or avian RSV strain, or a variant thereof. In certain embodiments, the wild-type F protein polypeptide is the F protein represented by SEQ ID NO: 1. To assist in understanding the present disclosure, all amino acid residue positions, regardless of strain, are given for (i.e., the positions of the amino acid residues are relative to) the amino acid positions of the exemplary F protein. The corresponding amino acid positions of the F proteins from other RSV strains can be easily determined by one of ordinary skill in the art by comparing the amino acid sequence of the selected RSV strain with the exemplary sequence using a readily available and well-known alignment algorithm (such as BLAST, for example, using default parameters).
[0142] The F2 polypeptide comprises at least a portion or all of amino acid residues 26-106 of SEQ ID NO: 1, e.g., 26-100, 26-102, 26-104, 26-105, or 26-106, except for the mutations introduced as described. The F1 polypeptide comprises at least a portion or all of amino acid residues 136-513 of SEQ ID NO: 1, e.g., 136-500, 140-500, 136-510, 136-512, or 136-513, except for the mutations introduced as described.
[0143] The C-terminus of the F2 domain can be position 100, 101, 102, 103, 104, 105 or 106 in the sequence of SEQ ID NO: 1. The C-terminus of the F2 domain is directly or through a linker connected to the N-terminus of the F1 domain. The N-terminus of the F1 domain can be position 136, 137, 138, 140, 141, 142, 143, 144, 145 or 146 in SEQ ID NO: 1. The C-terminus of the F1 domain can be position 499, 500, 502, 503, 504, 505, 506, 508, 510 or 513 in SEQ ID NO: 1. The C-terminus of the F1 domain can be directly or through a linker connected to a trimerization domain or a multimerization domain.
[0144] The term "N-type cysteine substitution" refers to a pair of cysteine substitutions in which one mutation site is between positions 137 and 216 of the F protein. Preferably, the distance between the two mutation sites is less than The difference between the distance before and after fusion is less than In the specification, Class N and Class RR1 have the same meaning and can be interchanged.
[0145] The term "Class C cysteine substitution" refers to a pair of cysteine substitutions in which one of the mutation sites is between positions 460 and 500 of the F protein. Preferably, the distance between the two mutation sites is less than The difference between the distance before and after fusion is less than In the manual, Class C and Class RR2 have the same meaning and can be interchanged.
[0146] The terms "multimerization domain" and "multimerization" refer to a polypeptide or a domain of a polypeptide that forms dimers, trimers, tetramers, pentamers, hexamers and / or 24-mers with other multimerization domains. Trimerization domains are for example foldon, GCN4 or MTQ.
[0147] In the present application, the term "GCN4" refers to the yeast transcription activator GCN4, which is a protein that binds to DNA through a leucine zipper (bZIP) structure. The sequence of GCN4 in the present application is IKRMKQIEDKIEEIESKQKKIENEIARIKKIK.
[0148] In the present application, the term "MTQ" is a trimerization motif, and the sequence of MTQ in the present application is IKEEIAKIKEEQAKIKEKIAEIEKRIAEIEKRIAGGCC.
[0149] Example 1. Plasmid construction, transformation and preparation
[0150] The amino acid sequences of each construct were designed according to Table 1 below, including the wild-type (WT) sequence, the ferritin sequence, the F ecto-Ferritin group sequence (the extracellular domain of the F protein + the ferritin sequence), and the DS-Cav1B group sequence. In addition, the DS-Cav1A group was designed by performing disulfide bond mutations S155C and S290C, and cavity-filling mutations S190F and V207L on the WT sequence. The DS-Cav1B group sequence was obtained by further performing amino acid substitution mutations P102A, I379V, and M447V on the DS-Cav1A group sequence.
[0151] The amino acid sequence was codon-optimized according to the host CHO cells to determine the nucleic acid sequence for gene synthesis.
[0152] Table 1: Construct amino acid sequence design
[0153] The synthesized target gene was inserted into the eukaryotic plasmid pCHO3.1 vector for transfection and expression. Each recombinant plasmid was transformed into competent E. coli DH5α cells. Glycerol cultures containing the target gene were transferred to 150 mL of LB liquid medium (final Amp concentration of 100 μg / mL) and cultured overnight at 37°C and 2000 rpm in a shaking incubator. Plasmids were extracted using an endotoxin-free plasmid extraction kit. The extracts were then assayed for plasmid concentration and subjected to enzyme digestion analysis. The specific reaction system is shown in Table 2.
[0154] Table 2: Enzyme digestion reaction system
[0155] After plasmid amplification, concentrations were measured, revealing that each plasmid achieved a high amplification concentration of approximately 600-900 μg / ml, with a total volume of approximately 1.0 μg. Enzyme digestion results were analyzed by 1% agarose gel electrophoresis, revealing clear bands at the corresponding sizes. Sequencing of all plasmids confirmed that the target gene sequences were correct. Recombinant plasmid vectors carrying the target gene were successfully transferred into host cells and amplified.
[0156] The plasmids with the following intermolecular cysteine substitution mutations were also constructed with reference to the above. After plasmid amplification, the amplification concentration of the plasmids with intermolecular cysteine substitution mutations (also called "intermolecular disulfide bond mutations") was examined. The results are shown in the following table.
[0157] Table 3: Plasmid concentration determination results
[0158] The results showed that the plasmids with higher amplification concentrations were mainly pCHO3.1-F46, pCHO3.1-F47, pCHO3.1-F48, pCHO3.1-F49 and pCHO3.1-F50.
[0159] Example 2. Protein expression
[0160] The obtained plasmid was introduced into CHO cells by transient transfection, and the protein supernatant was collected after culture.
[0161] ExpiCHO-S cells (Thermo) were cultured in EmCD CHO-S203 (Eminence / L20301) medium supplemented with 6 mM L-glutamine (Sigma / G5146). One day in advance, 0.25E5 cells / well were plated in 96-well plates (supplemented with 10% FBS) and incubated in a 37°C, 8% CO2 incubator. On the day of transfection, the 96-well plates containing the cells were replaced with fresh EmCD CHO-S203 medium containing L-glutamine. A transfection incubation system (50% of the transfection volume) was prepared using EmCD CHO-S203 medium supplemented with L-glutamine. DNA was added at 1 μg / ml and the transfection reagent PEI (Polysciences / 24765-1) to DNA ratio was 3. The PEI and DNA were mixed and incubated for 5 minutes before being added to a 96-well plate containing cells. The culture was incubated in a 37°C, 8% CO2 incubator. 24 hours after transfection, the temperature was lowered to 32°C and Advanced Feed 1 (Sigma / 24368-1L) was added at a 5% volume ratio. Seven days after transfection, the culture was stopped and the supernatant collected.
[0162] Example 3. Evaluation experiment on increasing protein expression
[0163] Two parallel sets of samples, DS-Cav1A and DS-Cav1B protein supernatants stored at 4°C, were tested using molecular sieve chromatography. The molecular sieve chromatography column used a 40:1 height-to-diameter ratio and Superdex 200 filler. The mobile phase consisted of 2.5% mercaptoethanol and 20 mmol / L Tris-HCl, pH 8.0. The flow rate was 50 cm / hr. The sample load was less than 5% (v / v) of the column bed volume, and the eluted peaks were collected stepwise (see Figures 1(A) and 1(B) for chromatograms and Figures 2(A) and 2(B) for electrophoresis results).
[0164] The applicant unexpectedly discovered that, in contrast, the three natural substitutions P102A, I379V, and M447V in DS-Cav1B can significantly increase protein expression. The DS-Cav1 used in the control experiments in the following examples refers to the optimized DS-Cav1B.
[0165] Example 4. Design of a single mutation strategy for F protein
[0166] Each mutant of the present invention is designed and prepared based on the wild-type (abbreviated WT) RSV F protein amino acid sequence described in SEQ ID NO:1. This embodiment illustrates the design of various F protein single mutants, which are provided in the form of trimers, including foldon domains and introduced amino acid mutations, such as cavity-filling mutations. These F protein single mutants include an IgG signal peptide (MGWSCIILFLVATATGVHS) and two separate polypeptide chains. One of the polypeptide chains, the F2 polypeptide, includes amino acids 26-106 of SEQ ID NO:1, except for the mutations introduced as described. The other polypeptide chain includes the F1 polypeptide (residues 136-513) connected to the N-terminus of the foldon domain. In addition, the modifications introduced include del_P27 being replaced with ARGSGSGSG, R106Q, and F137S. Additionally, a purification tag His-Tag (HHHHHHHH), an affinity tag Monoclonal Flag-Tag (DYKDDDDK), and a linker sequence (e.g., GSGSG) are included. The signal peptide (residues 1-25) and pep27 (residues 110-136) of SEQ ID NO: 1 are cleaved from the F0 precursor during the expression process.
[0167] The amino acid sequences of each RSV F protein mutant and control protein were designed according to the table below. The amino acid sequences were codon-optimized according to the host CHO cells to determine the nucleic acid sequence and perform gene synthesis.
[0168] Table 4: Mutants containing only cavity-filling mutations
[0169] In addition, a single F protein mutant containing only the linker sequence shown in the table below was designed. This was constructed by replacing residues 104-144 in the template amino acid sequence with the linker sequence. The amino acid sequence was codon-optimized according to the host CHO cells to determine the nucleic acid sequence and perform gene synthesis.
[0170] Template amino acid sequence:
[0171] Table 5: Linker sequence design
[0172] Plasmid transformation, preparation, and enzyme digestion were performed according to the methods of Example 1. After plasmid amplification, concentration was measured, and high amplification concentrations were achieved for each plasmid. Sequencing of all plasmids confirmed that the target gene sequences were completely correct. The recombinant plasmid vectors carrying the target gene were successfully transferred into host cells and amplified.
[0173] Example 5. Screening of intermolecular disulfide bond mutation schemes
[0174] The obtained plasmid was introduced into CHO cells by transient transfection, and the protein supernatant was collected after culture. The protein supernatant sample was diluted with PBS to 5 ng / μL with the coating antibody D25 or the coating antibody Motavizumab (abbreviated as Mota), and 200 μL was added to each well of a 96-well plate and incubated at 4°C overnight. Wash once with PBST. Block the ELISA detection plate with 250 μL 2% BSA / PBS, block for 1 hour at room temperature, and wash once with PBST. Add 200 μL of protein supernatant to each well and incubate at room temperature for 1 hour. Wash three times with PBST. Dilute the HRP-labeled antibody in 0.2% BSA / PBS to the appropriate dilution (D25-1:8000, Mota-1:16000), add 200 μL to each well, and incubate at room temperature for 1 hour. Wash four times with PBST. Add 100 μL of substrate solution (TMB two-component solution A:B = 1:1 mixture), react at room temperature for 15-20 min, add 100 μL of stop solution, and read the OD value.
[0175] Table 6: Binding of intermolecular disulfide bond mutants to D25 and Mota
[0176] Selection of intermolecular disulfide bond design schemes 1) refer to the OD value of the D25 antibody, 2) also refer to the OD value of the Mota antibody. F50, F51, F54, F56, and F49 are the mutants with the highest expression of different intermolecular disulfide bond mutation designs. Further combined with the measurement results of the plasmid concentration in Table 3 in Example 1, the preferred mutation designs include F49, F54, F50, and F56.
[0177] Example 6. Screening of N-type cysteine substitution mutation schemes
[0178] Regarding the screening of N-type cysteine substitution mutation schemes, the following single mutant plasmids were introduced into CHO cells by transient transfection. After culture, the protein supernatant was collected and placed at 4°C for 7 days before detection.
[0179] Dilute the coating antibody D25 or Motavizumab (Mota) in PBS to 5 ng / μL, add 200 μL to each well of a 96-well plate, and incubate overnight at 4°C. Wash once with PBST. Block the ELISA plate with 250 μL of 2% BSA / PBS at room temperature for 1 hour, then wash once with PBST. Add 200 μL of protein supernatant to each well and incubate at room temperature for 1 hour. Wash three times with PBST. Dilute the HRP-conjugated antibody in 0.2% BSA / PBS to the appropriate dilution (1:8000 for D25 and 1:16000 for Mota), add 200 μL to each well, and incubate at room temperature for 1 hour. Wash four times with PBST. Add 100 μL of substrate solution (TMB two-component solution A:B = 1:1), react at room temperature for 15-20 minutes, add 100 μL of stop solution, read the OD values for the different antibodies, and calculate the sample concentration according to the regression analysis equation. Calculate the activity concentration ratio of D25 to Mota after the protein is placed at 4°C for 7 days.
[0180] Table 7: OD values of N-type cysteine substituted mutants and the ratio of D25 to Mota concentration after 7 days
[0181] The disulfide bond design scheme for RR1 was selected based on 1) the OD value of the D25 antibody and 2) the OD value of the Mota antibody. F34, F30, F25, and F26 were the mutants with the highest expression among the different intermolecular disulfide bond mutation designs, with higher expression levels and antibody binding activity compared to the wild-type WT.
[0182] The PreF conformation ratio (concentration ratio in the last column) was further detected after the protein samples were placed at 4°C for 7 days. The results showed that the F27, F25, F26 and F30 protein supernatants could still be detected with a higher PreF conformation ratio after being placed at 4°C for 7 days, indicating that their N-type cysteine substitution mutation schemes are more conducive to maintaining the pre-fusion conformation of the F protein in a general vaccine storage environment. Therefore, the preferred N-type cysteine substitution mutations are F30, F27, F25 and F26.
[0183] Example 7. Screening of Class C Cysteine Substitution Mutation Schemes
[0184] Regarding the screening of class C cysteine substitution mutation schemes, the following single mutant plasmids were introduced into CHO cells by transient transfection, and the protein supernatant was collected after culture for detection.
[0185] Dilute the coating antibody Motavizumab (Mota) in PBS to 5 ng / μL, add 200 μL to each well of a 96-well plate, and incubate overnight at 4°C. Wash once with PBST. Block the ELISA plate with 250 μL of 2% BSA / PBS at room temperature for 1 hour, then wash once with PBST. Add 200 μL of protein supernatant to each well and incubate at room temperature for 1 hour. Wash three times with PBST. Dilute the HRP-conjugated antibody to the appropriate dilution (Mota - 1:16000) in 0.2% BSA / PBS, add 200 μL to each well, and incubate at room temperature for 1 hour. Wash four times with PBST. Add 100 μL of substrate solution (TMB two-component solution A:B = 1:1 mixture), react at room temperature for 15-20 minutes, add 100 μL of stop solution, and read the OD value.
[0186] Table 8: OD values of mutants with cysteine substitutions in class C
[0187] The RR2 disulfide bond design scheme was selected based on 1) the D25 antibody OD values and 2) the Mota antibody OD values. F42, F44, F41, and F45 were the most highly expressed RR2 disulfide bond mutations, demonstrating higher expression levels and antibody binding activity compared to the wild-type WT. Therefore, the preferred RR2 cysteine substitution schemes were I332C+S485C, F387C+I492C, I332C+P480C, and K399C+S485C.
[0188] Example 8. Screening of different types of disulfide bond mutation designs
[0189] RSV F mutant plasmids were designed according to the table below, including constructs with different types of cysteine mutations. The resulting plasmids were introduced into CHO cells via transient transfection. After incubation, the protein supernatant was collected and aliquoted into two samples, one stored at 4°C and the other heated at 60°C for 1 hour. The following assays were performed.
[0190] Dilute the coating antibodies Motavizumab (Mota) and D25 to 5 ng / μL in PBS, add 200 μL to each well of a 96-well plate, and incubate overnight at 4°C. Wash once with PBST. Block the ELISA plate with 250 μL of 2% BSA / PBS at room temperature for 1 hour, then wash once with PBST. Add 200 μL of protein supernatant to each well and incubate at room temperature for 1 hour. Wash three times with PBST. Dilute the HRP-conjugated antibody to the appropriate dilution (Mota - 1:16000) in 0.2% BSA / PBS, add 200 μL to each well, and incubate at room temperature for 1 hour. Wash four times with PBST. Add 100 μL of substrate solution (TMB two-component solution A:B = 1:1), react at room temperature for 15-20 minutes, add 100 μL of stop solution, read the OD value, and calculate the 60°C / 4°C concentration ratio.
[0191] Table 9: Concentration ratios of mutants with different types of cysteine mutations
[0192] The DS mutation in DS-Cav1 refers to S155C+S290C, which belongs to the RR1 class of mutations. The results showed that compared with the DS mutations in the DS-Cav1 design, the RR2 class of disulfide bond mutations F44 and F45, and the Inter class of disulfide bond mutations F50 and F49 were more thermally stable, indicating that proteins with RR2 or Inter class mutations have a stronger ability to maintain their three-dimensional structure and function under high temperature conditions. The thermal stability of F49 even exceeded that of DS-Cav1, which includes the combination of the disulfide bond mutations S155C+S290C and the cavity mutations S190F and V207L, indicating that the mutation design of F49 has stronger intermolecular forces.
[0193] The combined mutation of disulfide bonds F232 has a thermal stability comparable to that of DS-Cav1, while the combined mutation of F233 has a thermal stability superior to that of DS-Cav1 and stronger intermolecular forces.
[0194] Example 9. Evaluation of the thermal stability of the conformation of the intermolecular disulfide bond K75C+E218C
[0195] Referring to the intermolecular disulfide bond design scheme, we further designed polypeptides that introduced combinatorial mutations into RSV F ecto (extracellular domain), focusing on the combinatorial screening of intermolecular disulfide bond mutations.
[0196] The expressed candidate protein was prepared in large quantities and purified using a two-step purification method of nickel column affinity chromatography and molecular sieve chromatography. The protein concentration was diluted to the detection concentration, and the Pre-F prefusion conformation-specific monoclonal antibody D25 was used to identify the prefusion conformational stability of the purified protein after incubation for 1 hour.
[0197] In conjunction with the design of individual mutations in the protein, we first further investigated the effect of the intermolecular disulfide bond (inter disulfide bond) mutation K75C+E218C on the thermal stability of the F protein before fusion. The conformational thermal stability reference value is characterized by the sum of the D25 concentration ratios of different batches of protein after one hour of heat treatment and at 4°C. The conformational thermal stability reference value in the table below is mainly the sum of the D25 concentration ratios of two batches and three times, including the D25 concentration ratio of the 0512 batch of protein after one hour of treatment at 60°C and at 4°C, the D25 concentration ratio of the 0512 batch of protein after one hour of treatment at 70°C and at 4°C, and the D25 concentration ratio of the 0509 batch of protein after one hour of treatment at 70°C and at 4°C. The results are shown in the table below.
[0198] Table 10: Combinatorial screening of inter-disulfide bond mutations and conformational thermal stability evaluation
[0199] The results of thermal stability of the control group without intermolecular disulfide bonds are shown in the following table.
[0200] Table 11: Control combination screening and conformational thermal stability evaluation
[0201] In terms of the thermal stability of the PreF conformation, the protein samples were incubated at 60°C or 70°C for 1 hour. Compared with the F protein without the intermolecular disulfide bond design, the pre-fusion conformation of the F protein with the K75C+E218C mutation design and other combinations of the inter disulfide bond design was relatively stable. However, without the intermolecular disulfide bond K75C+E218C design, the stability of the protein would be significantly reduced.
[0202] Example 10. Evaluation of the thermal stability of PreF conformations of combined mutants with a granulation domain
[0203] Based on the preferred inter disulfide bond mutations, N-type disulfide bond mutations, and C-type disulfide bond mutations, a protein expressing a multimerization domain (ferritin particle domain) at the C-terminus of the polypeptide was prepared in large quantities according to the table below. The protein was purified using a two-step purification method of nickel column affinity chromatography and molecular sieve chromatography. The purified protein was placed at 4°C and incubated at 60°C for 1 hour. The protein concentration was then diluted to the detection concentration. The protein was then identified using the Pre-F prefusion conformation-specific monoclonal antibody D25, and the thermal stability of the protein's prefusion conformation was investigated.
[0204] Table 12: Design of combinatorial mutants with granulation domains
[0205] Table 13: Evaluation of thermal stability of pre-fusion conformations of combined mutants with particle domains
[0206] The results showed that both the purified protein stored at 4°C and the protein incubated at 60°C for 1 hour could bind to the prefusion conformation-specific monoclonal antibody D25, successfully preserving the prefusion conformation of the F protein. Although the prefusion conformation detected in some combined mutants decreased to varying degrees after heat treatment at 60°C, the prefusion conformation detected in F189, F192, and F194 remained almost unchanged, with D25 ratios (60°C / 4°C) of 1.07, 1.07, and 0.91, respectively. Taking into account the measured D25 concentrations, F189, F192, and F194 were preferred.
[0207] Example 11. Immunological evaluation
[0208] Female BALB / C mice aged 6-8 weeks were randomly divided into groups of 6. Mice were immunized with the vaccine via intramuscular injection on days 0 and 21, with 50 μL injected into each leg. The immunogens included candidate antigens F188 (SEQ ID NO: 12), F179 (SEQ ID NO: 13), F194 (SEQ ID NO: 14), and F196 (SEQ ID NO: 15), as well as a positive control group containing DS-Cav1 (SEQ ID NO: 4). A negative control group was also administered with PBS. The antigen dose was 12 μg per mouse, and the AS01 adjuvant dose was 1 / 20 HD per mouse.
[0209] AS01 adjuvant is a liposome-based adjuvant whose main components include MPL, QS-21, DOPC, and cholesterol. A 1-HD AS01 adjuvant (0.5 ml) contains 50 μg MPL, 50 μg QS-21, 1 mg DOPC, 0.25 mg cholesterol, 4.835 mg sodium chloride, 0.15 mg anhydrous disodium hydrogen phosphate, 0.54 mg potassium dihydrogen phosphate, and water for injection. Serum was collected on days 20 and 35 and stored at -20°C for subsequent testing for binding and neutralizing antibodies.
[0210] Combined antibody detection:
[0211] (1) Dilute the serum sample to be tested with sample diluent;
[0212] (2) The positive control serum was diluted 1:10,000 with sample diluent, and the negative control serum was diluted 1:200 with sample diluent;
[0213] (3) Sample loading: Serially diluted serum samples, negative control serum, positive control serum, and blank control solution (sample diluent is used as blank control) are added to the pre-F ELISA plate at 100 μl / well, with the serum sample added to 1 well and the control solution added to 2 wells; IgG-UNLB ELISA strips are added with sample diluent at 100 μl / well;
[0214] (4) Incubation: Incubate the ELISA plate at 37°C for 30 minutes and wash the plate five times with washing buffer in an automatic plate washer;
[0215] (5) Add enzyme: Add 100 μl / well of enzyme-labeled secondary antibody (HRP Goat Anti-Mouse IgG (H+L), ABclonal) to the ELISA plate, incubate at 37°C for 30 min, and wash the plate five times with washing buffer in an automatic plate washer;
[0216] (6) Color development: Mix equal volumes of color development solution A and color development solution B (Feijing Biotechnology), add 100 μl / well to the ELISA plate, and incubate at room temperature in the dark for 15 minutes;
[0217] (7) Termination: Add 50 μl / well of stop solution to terminate the reaction;
[0218] (8) Plate reading: Measure the absorbance at a wavelength of 450 nm (reference wavelength is 620 nm) using an enzyme reader. The results are shown in the table below.
[0219] Table 14: Pre-F specific IgG content (five-week serum)
[0220] After booster immunization, the pre-F IgG GMC (geometric mean concentration) detected in the serum of mice in each group at 5 weeks increased significantly to varying degrees compared to that at 3 weeks. The pre-F IgG GMC (geometric mean concentration) of F196 and F179 was higher than that of the positive control DS-Cav1 (referring to the PreF design concept of CN105473604B, including the pre-F trimer stabilized by a disulfide bond between residues 155 and 290 ("DS"), cavity-filling mutations S190F and V207L ("Cav1"), and an additional C-terminal foldon trimerization domain).
[0221] Neutralizing antibody detection:
[0222] Neutralizing antibodies are indicators of immune response that can specifically recognize antigenic neutralization sites on the surface of viruses, preventing viruses from invading cells and multiplying, thus protecting the body from harm. Zhongke Guobang was commissioned to perform neutralizing antibody testing using the RSV A2 strain using the fluorescent spot reduction neutralization test (FRNT). The specific steps are as follows:
[0223] (1) Sample preparation: Serum stored at -20°C was thawed at room temperature, heat-inactivated at 56°C for 30 min, taken out after 30 min and cooled to room temperature, and then the six serum samples in each group were fully mixed to obtain mixed serum samples for each group.
[0224] (2) Sample addition and dilution: 40-fold initial dilution, followed by 4-fold dilution, for 6 dilutions. Take a 96-well plate, with the second column as the cell control (CC) and the third column as the virus control (VC). Add the 20-fold diluted sample to wells B4-B11, use a multichannel pipette to gently mix the liquid in wells B4-B11, and then perform a 4-fold dilution until it reaches wells G4-G11. Take the positive reference and negative reference samples for addition and dilution.
[0225] (3) Virus dilution: Dilute the virus to 800-1200 FFU / well on ice and add it to all wells except the cell control.
[0226] (4) Place the above 96-well plate in a 37°C, 5% CO2 incubator and incubate for 1 hour.
[0227] (5) HEp-2 cells were digested and counted, and the number was adjusted to 2.0×10 using complete culture medium. 5 100 μL / well was added to a 96-well plate.
[0228] (6) Place the cells in a 37°C, 5% CO2 incubator for culture. After 24-28 hours, use a cell imaging multifunctional microplate detection system to count the GFP fluorescent spots and record the results.
[0229] (7) 50% neutralizing antibody inhibition rate (ND 50 ) calculation: the fluorescence spot values read by the instrument are input into the data analysis template, and the 50% neutralizing antibody inhibition rate (ND 50 ).
[0230] We also commissioned Beijing Yunling Metrology and Testing Co., Ltd. to perform supplementary testing, primarily using the RSV long strain via the CPENT method with a luciferase reporter gene and chemiluminescence. The results are shown in the table below.
[0231] Table 15: Neutralizing Antibody Titers
[0232] It can be seen from the above experiments that the antigen and vaccine composition provided by the present invention can induce the production of high-titer neutralizing antibodies against RSV virus, and the neutralization effect on RSV is better than that of the positive control groups. This also suggests that the vaccine will provide better protective effects when the virus invades, which is of great significance to the research and development of RSV candidate vaccines.
[0233] Example 12. Immunological evaluation of different adjuvants
[0234] A screening study of RSV vaccine antigen (SEQ ID NO: 15) doses and different adjuvants was conducted in a BALB / c mouse model. Blood was collected and tested 14 days after the last immunization using the FRNT (type A) assay. Each mouse received an intramuscular injection of 0.1 ml of the vaccine. The results are shown in Figure 3 (neutralizing antibody titers in BALB / c mice immunized with RSV vaccine antigen and different adjuvants). Neutralizing antibody titers were higher in the AS03 adjuvant group than in the half-dose AS01 adjuvant group, demonstrating that the AS03 adjuvant group is superior to the half-dose liposome adjuvant group. The human dosage of the oil-in-water emulsion can consist of 5-15 mg of squalene, 5-15 mg of tocopherol, and 2-5.5 mg of Tween. The preferred dose of the antigen is 120 μg per person.
[0235] Table 16: Mouse testing groups of different doses of F196 and different adjuvants
[0236] Example 13. Immunological evaluation of cross protection of candidate antigens
[0237] A screening study of RSV vaccine antigen doses and different adjuvants for F194 (SEQ ID NO:14) and F196 (SEQ ID NO:15) in a mouse (BALB / c) model was conducted. The detection method was FRNT (test strain B subtype 18537). Blood was collected and tested 14 days after the last immunization. The evaluation results are shown in Figure 4 (Nutriental antibody titers of cross-protection of RSV vaccine antigens against subtype B virus in mice (BALB / c)). Neutralizing antibody titers were higher in the AS03 adjuvant group than in the half-dose AS01 adjuvant group, indicating that the AS03 adjuvant group is superior to the half-dose liposome adjuvant group. The human dosage of the oil-in-water emulsion can be 5-15 mg of squalene, 5-15 mg of tocopherol, and 2-5.5 mg of Tween. The positive control group was the GSK marketed vaccine AREXVY (antigen batch number 4JY53).
[0238] Table 17: Detection grouping of RSV antigens against recombinant RSV B-GFP virus
[0239] The RSV virus subtype used for the test is 18573. Figure 4 of the test results shows that the type A antigens F194 and F196 have cross-protective immune effects, just like the type A RSV recombinant vaccine marketed by GSK.
[0240] Example 14. Immunological evaluation of different antigen doses
[0241] In a study of the immunogenicity of RSV vaccines F194 (SEQ ID NO:14) and F196 (SEQ ID NO:15) in large-eared white rabbits, the animals were immunized using a two-dose schedule, three weeks apart. The doses of the immunizing antigen were 60 μg or 120 μg, and the adjuvant was 1 / 2 HD AS01. Blood samples were collected 14 days after each immunization and analyzed. The results are shown in Figure 5 (neutralizing antibody titers against type A virus in large-eared white rabbits immunized with RSV vaccine antigen) and Figure 6 (cross-protective neutralizing antibody titers against type B virus in large-eared white rabbits immunized with 120 μg of RSV vaccine antigen).
[0242] Table 18: Test groups for different doses of RSV antigen
[0243] The dosage of type A antigens F194 and F196 can be 60 μg or 120 μg. The neutralizing antibody titer of 60 μg is higher than that of 120 μg, indicating that the vaccine antigen dosage within the range of 60 to 120 μg can stimulate the body to produce a strong immune response. On the other hand, Figure 6 shows that 120 μg of type A antigens F194 and F196 have cross-protective immune effects against type B viruses.
[0244] Example 15. Immunological evaluation of bivalent vaccine antigens
[0245] A comparative study on the immune evaluation of mice (BALB / c) using a bivalent vaccine composed of RSV antigens consisting of type A F194 (SEQ ID NO: 14), F196 (SEQ ID NO: 15) and F194 B subtype (SEQ ID NO: 16), F196 B subtype (SEQ ID NO: 17) and a monovalent vaccine. The detection method was FRNT (type B). Blood was collected and tested 14 days after the second immunization (0 days and 21 days). The immunization method was intramuscular injection of 0.1 ml per mouse. The evaluation results are shown in Figure 7 (Type B virus neutralizing antibody titer in mice (BALB / c) after immunization with RSV bivalent vaccine antigens).
[0246] Table 19: Experimental group table for the immunogenicity study of bivalent vaccine
[0247] The immunization results are shown in Figure 7. The immunization data show that the neutralizing antibody levels of the F194 and F196 bivalent vaccine adjuvant groups are significantly higher than those of the non-adjuvant groups. Numerically, the neutralizing antibody titers of the bivalent vaccine group against subtype B virus are also higher than those of the monovalent vaccine group and the DS-Cav1 control group.
[0248] Example 16. Structural studies on disulfide bond mutations
[0249] Based on the resolved post [McLellan et al., https: / / doi.org / 10.1128 / JVI.00555-11] and pre [McLellan et al., https: / / doi.org / 10.1126 / science.1234914] crystal structures, the specific sites for disulfide bond mutation design were investigated to illustrate the design and properties of the RSV F protein stabilized in its prefusion form.
[0250] The following figure shows the mutation design of the inter-molecular disulfide bond of the RSV F protein before fusion. The amino acid residues at positions 75 and 218 between the two monomers of the F protein (highlighted in light blue in the ribbon diagram) are separated by two amino acids in the pre-fusion conformation of Figure 8 (F49 (K75C + E218C)). ), it is expected that the disulfide bonds in the F49(K75C+E218C) construct can lock the recombinant RSV F protein in the prefusion conformation, protect the spacing unchanged, and make the prefusion F protein structure of the trimer more stable.
[0251] The design of N-type disulfide bond mutations is shown in the figure below. In the ribbon diagram, the distance between two amino acids I148C+Y286C, S55C+L188C, H159C+I291C, and G151C+I288C in the prefusion conformation and postfusion conformation of the RSV F protein is highlighted in dark blue, as shown in Figure 9 (the substitution sites in the prefusion conformation of the RSV F protein with N-type cysteine substitutions are less than ), it is expected that the disulfide bonds in the I148C+Y286C, S55C+L188C, H159C+I291C and G151C+I288C constructs can lock the recombinant RSV F protein in the prefusion conformation, making the prefusion F protein structure of the trimer more stable.
[0252] The design of class C disulfide bond mutations is shown in the figure below. In the ribbon diagram, the distance between two amino acids K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C, or F387C+I492C in the prefusion conformation and postfusion conformation of the RSV F protein is highlighted in dark blue, as shown in Figure 10 (the substitution sites in the prefusion conformation of the RSV F protein with class C cysteine substitutions are less than ), it is expected that the disulfide bonds in the K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C or F387C+I492C constructs can lock the recombinant RSV F protein in the prefusion conformation, making the prefusion F protein structure of the trimer more stable.
[0253] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. A recombinant RSV polypeptide comprising a recombinant RSV F protein ectodomain corresponding to amino acid residues 26-513 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1, characterized in that Compared to wild-type RSV F protein, the RSV F protein has one or a combination of the following mutations: AN type cysteine substitution mutations, wherein the site of the N type cysteine substitution is between residues 137-216 of the wild-type RSV F protein amino acid sequence, including 1 or 2 pairs of cysteine substitutions; Class BC cysteine substitution mutations, wherein the site of the Class C cysteine substitution is between residues 460-500 of the wild-type RSV F protein amino acid sequence, including 1 or 2 pairs of cysteine substitutions; C. Intermolecular cysteine substitution mutation, wherein the intermolecular cysteine substitution is selected from one or two pairs of V144C+I407C, K75C+E218C, S146C+N460C and A149C+Y458C.
2. The polypeptide of claim 1, wherein the N-type cysteine substitution mutation is selected from one or two pairs of I148C+Y286C, S55C+L188C, H159C+I291C and G151C+I288C.
3. The polypeptide of claim 1, wherein the class C cysteine substitution mutation is selected from one or two pairs of K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C and F387C+I492C.
4. A recombinant RSV polypeptide comprising a recombinant extracellular domain of RSV F protein corresponding to amino acid residues 26-513 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1, wherein the recombinant extracellular domain comprises a combination of the following cysteine substitution mutations: A. Intermolecular cysteine substitution mutations are selected from one or two pairs of V144C+I407C, K75C+E218C, S146C+N460C and A149C+Y458C; B, N-type cysteine substitution mutation, one of which is at position 137 to 216 of the F protein; C. Class C cysteine substitution mutations, one of which is located between positions 460 and 500 of the F protein.
5. The polypeptide of claim 4, wherein the one mutation site at positions 137 to 216 of the F protein is one or two pairs selected from I148C+Y286C, S55C+L188C, H159C+I291C and G151C+I288C; wherein the one mutation site at positions 460 to 500 of the F protein refers to K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C or F387C+I492C.
6. The polypeptide of claim 5, wherein the recombinant extracellular domain comprises a combination of the following cysteine substitution mutations: A, an intermolecular cysteine substitution mutation selected from V144C+I407C and / or K75C+E218C; B. N-type cysteine substitution mutation selected from I148C+Y286C, G151C+I288C or H159C+I291C; C. Class C cysteine substitution mutation selected from F387C+I492C, K399C+S485C or T323C+I475C.
7. A recombinant RSV polypeptide comprising a recombinant extracellular domain of RSV F protein corresponding to amino acid residues 26-513 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1, characterized in that: The recombinant extracellular domain has cysteine mutations K75C+E218C and / or V144C+I407C compared to the wild-type RSV F protein.
8. The polypeptide according to claim 7, characterized in that Compared with wild-type RSV F protein, there are cysteine mutations I148C+Y286C or S55C+L188C.
9. The polypeptide according to claim 7, characterized in that Compared with wild-type RSV F protein, there are cysteine mutations K399C+S485C or F387C+I492C.
10. The polypeptide of claim 7, wherein the recombinant extracellular domain comprises one of the following combinations of cysteine substitution mutations: A, V144C+I407C, K75C+E218C, I148C+Y286C, and F387C+I492C; B, V144C+I407C, I148C+Y286C, S55C+L188C, and F387C+I492C; C. K75C+E218C, I148C+Y286C, T323C+I475C; D. K75C+E218C, I148C+Y286C, F387C+I492C; E. K75C+E218C, I148C+Y286C, K399C+S485C; F, K75C+E218C, G151C+I288C, K399C+S485C; G, K75C+E218C, H159C+I291C, K399C+S485C.
11. A polypeptide as described in any one of claims 1 to 10, wherein the recombinant extracellular domain further comprises a cavity filling mutation, and the cavity filling mutation site is selected from positions 67, 495, 296 and 190 of the wild-type RSV F protein amino acid sequence; preferably, the cavity filling mutation is N67F or N67F+S190V+V296F+V495L.
12. The polypeptide of claim 11, wherein the recombinant extracellular domain further comprises mutations P102A+I379V+M447V, S46G or G184N that increase expression.
13. The polypeptide of any one of claims 1-10, wherein the recombinant extracellular domain comprises a recombinant F2 domain comprising at least amino acid residues 26-105 of the RSV F protein and a recombinant F1 domain comprising at least amino acid residues 145-513 of the RSV F protein. The polypeptide of claim 13 , wherein the recombinant F2 domain is connected to the recombinant F1 domain directly or through a linker.
15. The polypeptide according to claim 14, wherein the recombinant F2 domain is connected to the recombinant F1 domain via a linker, which means that residues 106-144 of the recombinant extracellular domain of the F protein are replaced by a linker selected from GGPGGS, GAPEPGE or GGSGGSG.
16. The polypeptide of any one of claims 1-15, wherein the C-terminus of the polypeptide comprises a trimerization domain or a multimerization domain.
17. The polypeptide of claim 16, wherein the trimerization domain is a foldon, GCN4 or MTQ domain and the multimerization domain is a ferritin domain.
18. Use of the polypeptide according to any one of claims 1 to 17 in the preparation of a vaccine for preventing RSV infection.
19. A vaccine for preventing RSV infection, comprising the polypeptide of any one of claims 1-17; the vaccine provides protection against infection by at least one of RSV subtype A and / or subtype B.
20. The vaccine for preventing RSV infection according to claim 19, comprising an adjuvant in the form of liposomes.
21. The vaccine for preventing RSV infection as claimed in claim 20, wherein the components of the adjuvant in the form of liposomes include MPL, QS-21 and cholesterol.
Citation Information
Patent Citations
Prefusion RSV F proteins and their use
CN105473604A
RSV f protein mutants
CN108738312A
Substitutions-modified prefusion RSV f proteins and their use
CN109069611A
Recombinant RSV F protein and application thereof
CN117304278A
Recombinant RSV F protein and application thereof
CN117304279A
